---
title: "Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296549016.md"
description: "Key findings from Phase 2b trials are guiding the development of a functional cure approach for Hepatitis B Virus (HBV), with more results anticipated in the second half of 2026. Promising developments in discovery programs are gaining traction, notably the mRNA cancer vaccine BRII-5395 advancing to clinical assessment for Hepatocellular Carcinoma (HCC). The company's robust financial standing enables sustained strategic progress."
datetime: "2026-08-21T00:12:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296549016.md)
  - [en](https://longbridge.com/en/news/296549016.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296549016.md)
generator: "portal-rs"
---

# Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

Key findings from Phase 2b trials are guiding the development of a functional cure approach for Hepatitis B Virus (HBV), with more results anticipated in the second half of 2026. Promising developments in discovery programs are gaining traction, notably the mRNA cancer vaccine BRII-5395 advancing to clinical assessment for Hepatocellular Carcinoma (HCC). The company's robust financial standing enables sustained strategic progress.

### Related Stocks

- [02137.HK](https://longbridge.com/en/quote/02137.HK.md)

## Related News & Research

- [Brii Biosciences Posts Promising Phase 2b Hepatitis B Data but Elebsiran Future Clouded by Arbitration](https://longbridge.com/en/news/291598680.md)
- [Brii Biosciences: Loss narrowed 32% to RMB101M as HBV and RNA pipelines advanced; cash at RMB1.77B](https://longbridge.com/en/news/296544440.md)
- [YieldMax MRNA Option Income Strategy ETF announces weekly distribution of $0.6420](https://longbridge.com/en/news/298597598.md)
- [Cionic Real-World Evidence Study Examines Quality of Life Across Upper Motor Neuron Conditions](https://longbridge.com/en/news/298445733.md)
- [Moderna (NASDAQ:MRNA) CFO Sells $4,685,093.64 in Stock](https://longbridge.com/en/news/298963121.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**